共 50 条
Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer® Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer
被引:26
|作者:
Erber, Ramona
[1
]
Stoehr, Robert
[1
]
Herlein, Stefanie
[1
]
Giedl, Claudia
[1
]
Rieker, Ralf Joachim
[1
]
Fuchs, Florian
[2
]
Ficker, Joachim H.
[3
]
Hartmann, Arndt
[1
]
Veltrup, Elke
[4
]
Wirtz, Ralph M.
[4
,5
]
Brueckl, Wolfgang M.
[3
]
机构:
[1] Friedrich Alexander Univ Erlangen Nurnberg FAU, Inst Pathol, Univ Hosp, Erlangen, Germany
[2] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Med Gastroenterol Pneumonol & Endocrinol 1, Univ Hosp, Erlangen, Germany
[3] Paracelsus Med Univ Nuernberg, Gen Hosp Nuernberg, Dept Resp Med Allergol & Sleep Med, Nurnberg, Germany
[4] STRATIFYER Mol Pathol GmbH, Cologne, Germany
[5] St Elizabeth Hosp, Inst Pathol, Cologne, Germany
关键词:
PD-L1;
PD-1;
NSCLC;
lung cancer;
pembrolizumab;
nivolumab;
E1L3N;
28-8;
immunohistochemistry;
EBUS-TBNA;
mRNA;
SQUAMOUS-CELL;
NIVOLUMAB;
DOCETAXEL;
D O I:
10.21873/anticanres.12137
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Background: Immunohistochemical (IHC) assessment of programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) has become important since the development of anti-PD-1/-PD-L1 directed drugs. Various PD-L1 antibodies and cut-offs have been used in different trials to predict response to these drugs, thus comparison of those studies is difficult. We compared PD-L1 mRNA expression measured by RT-qPCR with PD-L1 protein expression evaluated by IHC. Moreover, we investigated the impact of different tumour tissue acquisition methods on the reliability of PD-L1 measurement techniques. Materials and Methods: NSCLC cases (N=22), including n=9 mediastinal lymph node biopsies acquired by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and n=5 metastases, were evaluated prospectively for PD-L1 protein on tumor cells (TC) and immune cells (IC) using E1L3N and 28-8 antibodies and PD-L1 mRNA using the CheckPoint TYPER (R) assay. Results: In primary NSCLC tissues, agreement between PD-L1 mRNA and TC staining using the 28-8 antibody was excellent (kappa=0.85, p=0.0002). Comparing both PD-L1 antibodies against each other showed a kappa value of 0.58 (p=0.0106). In EBUS-TBNA, PD-L1 mRNA correlated perfectly with the 28-8 antibody (kappa=1.0, p=0.0023). PD-L1 mRNA levels significantly differed when comparing 28-8 TC staining of tumours >49% with 1-49% and 0% (p=0.0040; p=0.0081, respectively). In metastatic lesions, differences between PD-L1 mRNA and IHC became apparent (kappa=0.2, p=0.2525). Conclusion: Testing of PD-L1 mRNA and 28-8 IHC showed an excellent agreement in NSCLC samples including mediastinal lymph node biopsies. Since PD-L1 expression in >50% TC detected by 28-8 IHC can be reliably detected by RT-qPCR, quantitative PD-L1 mRNA determination should be considered as an alternative to IHC as there is no interobserver variability in RNA results.
引用
收藏
页码:6771 / 6778
页数:8
相关论文